Lupin and Novartis Resolve Patent Dispute Over Hypertension Drug

Indian pharmaceutical company Lupin and Swiss pharmaceutical group Novartis have reached an out-of court settlement over Novartis's hypertension drug sold under the brand name Lotrel, reported The Economic Times.

According to the news source, the settlement allows Lupin to launch a generic version of the drug ahead of its patent expiry in 2017 and get a one-time revenue upside.

Lupin intends to launch its generic version of Lotrel, a combination of amlodipine besylate and benazepril hydrochloride, within the next few years.

 

Comments

Post a Comment

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Image
GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut    Vox Author of GOP Tax Plan Says Children's Health Insurance Program Is Held Up “Because We Don't Have Money ...    The Intercept Nevada wins short reprieve in child health care funds fight    Sacramento Bee Ben McAdams: Congress to Tiny Tim: 'No health insurance for you.'    Salt Lake Tribune Full coverage
Read more

Trump wants more mental health care; Alabama says it's trying

Image
Trump wants more mental health care; Alabama says it's trying    AL.com Budget undercuts Trump focus on mental health, school safety    Yahoo News Mental health awareness license plates offered by New York State DMV    Buffalo News Trump wants to 'tackle the difficult issue of mental health?' He should put his money where his mouth is.    Washington Post Full coverage
Read more